Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

82.38EUR
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
€82.38
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
560,199
52-wk High
€115.20
52-wk Low
€80.92

Latest Key Developments (Source: Significant Developments)

Merck And Bluebird Bio Sign Supply Agreement For Commercial Production Of Viral Vectors
Wednesday, 20 Dec 2017 08:05am EST 

Dec 20 (Reuters) - MERCK KGAA ::MERCK AND BLUEBIRD BIO SIGN SUPPLY AGREEMENT FOR COMMERCIAL PRODUCTION OF VIRAL VECTORS.  Full Article

Merck KGaA ‍Receives Approval (Updated Registration) For Cladribine Tablets In Australia​
Thursday, 7 Dec 2017 04:11am EST 

Dec 7 (Reuters) - Merck KGaA ::SAYS ‍RECEIVES APPROVAL (UPDATED REGISTRATION) FOR CLADRIBINE TABLETS IN AUSTRALIA​.  Full Article

Merck Says Anand Nambiar, MD, Assigned As Head Of Integrated Circuit Materials Unit Of Merck KGaA
Wednesday, 6 Dec 2017 03:12am EST 

Dec 6 (Reuters) - Merck Ltd ::SAYS ANAND NAMBIAR, MD, HAS ACCEPTED NEW ASSIGNMENT AS 'HEAD OF INTEGRATED CIRCUIT MATERIALS' UNIT OF MERCK KGAA.SAYS NAMBIAR TO REMAIN CO'S MD UNTIL MARCH 31, 2018.  Full Article

Merck KGAA, Darmstadt Announces FDA 510(K) Clearance Of Genea Biomedx’S Fertility Benchtop Incubator Geri
Tuesday, 5 Dec 2017 08:22am EST 

Dec 5 (Reuters) - Merck Kgaa ::MERCK KGAA, DARMSTADT, GERMANY ANNOUNCES FDA 510(K) CLEARANCE OF PARTNER GENEA BIOMEDX’S FERTILITY BENCHTOP INCUBATOR GERI™.MERCK KGAA - U.S. COMMERCIAL AVAILABILITY FOR GERI ‍EXPECTED IN FIRST HALF OF 2018 ​.  Full Article

Merck KgaA Says FDA 510(K) Clearance Of Benchtop Embryo Incubator Geri
Tuesday, 5 Dec 2017 08:19am EST 

Dec 5 (Reuters) - MERCK KGAA ::ANNOUNCES FDA 510(K) CLEARANCE OF PARTNER GENEA BIOMEDX’S FERTILITY BENCHTOP INCUBATOR GERI.U.S. COMMERCIAL AVAILABILITY EXPECTED IN FIRST HALF OF 2018.  Full Article

Merck And Pfizer Provide Update On Phase III Javelin Gastric 300 Study In Patients With Pre-Treated Advanced Gastric Cancer
Tuesday, 28 Nov 2017 08:01am EST 

Nov 28 (Reuters) - Pfizer Inc ::MERCK AND PFIZER PROVIDE UPDATE ON PHASE III JAVELIN GASTRIC 300 STUDY IN PATIENTS WITH PRE-TREATED ADVANCED GASTRIC CANCER.MERCK KGAA- ‍PHASE III JAVELIN GASTRIC 300 TRIAL DID NOT MEET ITS PRIMARY ENDPOINT ​.MERCK KGAA- ‍SAFETY PROFILE OF AVELUMAB WAS CONSISTENT WITH THAT OBSERVED IN OVERALL JAVELIN CLINICAL DEVELOPMENT PROGRAM​.MERCK KGAA - ‍OUTCOME OF JAVELIN GASTRIC 300 DOES NOT HAVE ANY IMPACT ON CURRENT AVELUMAB APPROVALS​.MERCK KGAA - ‍JAVELIN GASTRIC 300 DATA WILL BE FURTHER EXAMINED TO BETTER UNDERSTAND RESULTS; WILL BE SUBMITTED FOR PRESENTATION AT MEDICAL CONGRESS​.  Full Article

Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt
Monday, 13 Nov 2017 08:08am EST 

Nov 13 (Reuters) - Orexigen Therapeutics Inc :Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt, Germany for contrave in Latin America.Orexigen Therapeutics - ‍Orexigen will receive an upfront payment and other potential regulatory and sales milestones, which have not been disclosed​.Orexigen Therapeutics Inc - ‍merck KGaA, Darmstadt, Germany will be responsible for all commercialization and regulatory activities ​.Orexigen Therapeutics Inc - ‍Orexigen will also be responsible for product supply​.Orexigen Therapeutics Inc - ‍under terms of agreement, Merck KGaA, Darmstadt, Germany will own marketing authorization in region​.  Full Article

BRIEF-Merck KGaA, Samsung Biologics sign MoU on strategic alliance
Wednesday, 1 Nov 2017 02:11am EDT 

Corrects company name in headline:Says MilliporeSigma signs memorandum of understanding (MoU) with Samsung Biologics for strategic alliance on biopharma manufacturing, biologics process development‍​.The new MoU is an extension of one signed in 2014 that encompasses a long-term supply agreement.  Full Article

GSK will look at Pfizer, Merck consumer assets if offered for sale
Wednesday, 25 Oct 2017 07:47am EDT 

Oct 25 (Reuters) - GlaxoSmithKline CEO Emma Walmsley tells reporters::as world leader in consumer healthcare, we will look at Pfizer consumer health.bulking up consumer is one option but top priority is boosting pharma pipeline.moving forward with Brexit contingency planning, would like to know about transition asap.needs clarity on Brexit implementation phase of at least 2 years.not thinking of any relocation out of UK as a result of brexit.would also look carefully at German Merck consumer assets.new pharma head Miels very focused on launch of 3 critical new products.happy to continue to work with Novartis on consumer health or take over stake if Novartis wants to sell.  Full Article

Merck KGaA: Canadian patent office to grant patent application for CRISPR technology
Tuesday, 24 Oct 2017 08:12am EDT 

Oct 24 (Reuters) - MERCK KGAA ::MERCK KGAA - CANADIAN PATENT OFFICE TO GRANT MERCK KGAA, DARMSTADT, GERMANY'S PATENT APPLICATION FOR CRISPR TECHNOLOGY.FIRST PATENT ALLOWANCE FOR COMPANY’S CRISPR TECHNOLOGY IN NORTH AMERICA‍​.  Full Article

BRIEF-Merck KGaA Invests Additional $47 Mln To Enhance Manufacturing And Distribution In Asia

* MERCK KGAA, DARMSTADT, GERMANY INVESTS ADDITIONAL $47 MILLION TO ENHANCE MANUFACTURING AND DISTRIBUTION IN ASIA